Publications (2)3.49 Total impact
-
Article: Human leukocyte antigen-A, -B, and -DRB1 alleles and sarcoidosis in Chinese Han subjects.
[show abstract] [hide abstract]
ABSTRACT: Human leukocyte antigens (HLA) play a key role in antigen presentation. HLA genes, especially HLA-A, -B, and -DRB1, which are highly polymorphic, have been thought to be candidate loci for the etiology of sarcoidosis. This study aimed to assess the association between the polymorphism of HLA-A, -B, and -DRB1 alleles and sarcoidosis in Chinese Han subjects. Genomic DNA was extracted from 131 patients with sarcoidosis and 122 healthy controls. The polymorphisms of the HLA-A, -B, and -DRB1 alleles were determined using a polymerase chain reaction sequence-specific primer method. The frequency of allele HLA-DRB1*11 in sarcoidosis patients was significantly higher than that in controls (24.43% vs 4.92%, p/p(c) = 0.0001/0.002), whereas the frequencies of allele HLA-B*13 and HLA-DRB1*07 were markedly lower in sarcoidosis patients than in controls (12.21% vs 27.87%, p/p(c) = 0.002/0.045; 7.63% vs 22.95%, p/p(c) =0.001/0.009). HLA-B*51 was overrepresented in patients with erythema nodosum and Löfgren's syndrome (p < 0.001 [p(c) = 0.015], p < 0.0001 [p(c) < 0.001], respectively). These results support the hypothesis that HLA-A, -B, and -DRB1 polymorphisms may play a role in susceptibility and manifestation of sarcoidosis.Human immunology 07/2011; 72(7):571-5. · 2.55 Impact Factor -
Article: Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases.
[show abstract] [hide abstract]
ABSTRACT: Patients with diffuse panbronchiolitis (DPB) are routinely treated with erythromycin, clarithromycin, and roxithromycin. The clinical effect of azithromycin on DPB has not been confirmed in a large cohort. The present study was undertaken to investigate the clinical effects of azithromycin on patients with DPB. Fifty-one patients with DPB treated with azithromycin in Shanghai Pulmonary Hospital, China, from July 2001 to April 2007 were analyzed retrospectively. Azithromycin (500 mg a day) was administrated intravenously in the first 1-2 weeks, taken orally (500 mg, once a day) for 3 months, and tapered to 3 times a week for 6-12 months. The patients were followed up until September 1, 2009. The therapeutic effect, according to their clinical and radiological findings, arterial gas analysis, lung function, and sputum bacterium before and after the therapy, was categorized into the following five grades: 1) cured; 2) improved; 3) no response; 4) aggravation, and 5) relapse. With azithromycin therapy, 14 (27.5%) patients with DPB were completely cured. The symptoms were eliminated to certain degrees for the other 36 cases (70.6%) of DPB. Five-year survival in this cohort was 94.1%. Azithromycin is effective and well tolerated for patients with diffuse panbronchiolitis.Internal Medicine 01/2011; 50(16):1663-9. · 0.94 Impact Factor
